# The Molecular Glue Degrader Landscape in 2022
## Highlights from Disclosed Molecular Glue Degraders
### from CAS Insights Article

## clinical highlights



PDB: 6XK9

**CC-90009 (eragidomide)**
CRBN-based GSPT1 degrader
in Ph. I for AML + MDS
GSPT1 $DC_{50}$ = 9 nM, $D_{max}$ = 51% (4 h)
from phenotypic screening of CRBN mod. library
**CAS RN: 1860875-51-9**
CELGENE/BMS



PDB: n/a

**CFT7455**
CRBN-based IZKF1/3 degrader
In Ph. I/II for r/r NHL + MM
IKZF1 $DC_{50}$ = 0.17 nM, $E_{max}$ = 20% (1.5h)
from phenotypic screening of CRBN monoDAC library
**CAS RN: 2504235-67-8**
C4 THERAPEUTICS



PDB: 7UGF

**NVP-DKY709**
CRBN-based IKZF2 degrader
in Ph. I/Ib for solid tumors (NSCLC, melanoma)
IKZF2 $DC_{50}$ = 11 nM, $D_{max}$ = 69% (16-20h)
from IKZF2-CRBN recruitment assay
**CAS RN: 2291360-73-9**
NOVARTIS



PDB: 6Q0R

**E7820**
DCAF15–based RBM23/39 degrader
in Ph. II for AML, MDS + CMML
RBM39 $DC_{50}$ = 17 nM, $D_{max}$ = 46% (24h)
from sandwich TF screening assay
**CAS RN: 289483-69-8**
EISAI

## preclinical highlights

PBD: 6TD3



**(R)-CR8**
CRL4-based cyclin K degrader
DBBI/CR8-CDK12-cyclin K complex $K_{app}$ ≤ 100 nM
from data mining of 4.5K library
**CAS RN: 294646-77-8**
BROAD/FRIEDRICH MIESCHER (FMI)

PDB: n/a



**TMX-4116**
CRBN-based CK1α degrader
CK1α $DC_{50}$ < 200 nM (4h)
from selectivity opt. of known IMiDs
**CAS RN: 2766385-56-0**
DANA-FARBER/STANFORD

PDB: n/a



**NRX-252114**
β-TrCP–based β-catenin degrader
pSer33/S37A β-catenin $EC_{50}$ = 6.5 nM, $K_d$ = 0.4 nM
from HTS of 350K library
**CAS RN: 2763260-39-3**
NURIX THERAPEUTICS

PDB: 6XMX



**BI-3802**
SIAH1–based BCL6 degrader
BCL6 $IC_{50}$ ≤ 3nM, 80% degradation (5 μM, 90 min)
from HTS of 1.7M library
**CAS RN: 2166387-65-9**
BOEHRINGER INGELHEIM

drug hunter

drughunter.com

**Access the 2022 CAS Insights article here: drughunters.com/molglues**